Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies
https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-and-genethon-announce-collaboration-to-develop-imlifidase-as-pre-treatment-to-gene-therapy-in-crigler-najjar-syndrome-patients-with-anti-aav-antibodies/
https://www.hansabiopharma.com/media/press-releases/2023/hansa-biopharma-and-genethon-announce-collaboration-to-develop-imlifidase-as-pre-treatment-to-gene-therapy-in-crigler-najjar-syndrome-patients-with-anti-aav-antibodies/
